Arterial thrombosis-insidious, unpredictable and deadly

Nature Medicine

Volumn 17, Issue 11, 2011, Pages 1423-1436

  Jackson, Shaun P ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ATOPAXAR; AZD 6482; CANGRELOR; CILOSTAZOL; CLOPIDOGREL; DIPYRIDAMOLE; ELINOGREL; EPTIFIBATIDE; PRASUGREL; TERUTROBAN; THROMBIN; TICAGRELOR; TICLOPIDINE; TIROFIBAN; UNCLASSIFIED DRUG; VORAPAXAR;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ARTERY THROMBOSIS; ATHEROSCLEROSIS; BLEEDING; BLOOD CLOTTING; BLOOD VESSEL OCCLUSION; CARDIOVASCULAR RISK; DIARRHEA; DISEASE COURSE; DIZZINESS; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FLUSHING; GASTROINTESTINAL TOXICITY; HEADACHE; HEART PALPITATION; HEMOSTASIS; HUMAN; HYPOTENSION; NEUTROPENIA; NONHUMAN; PANCYTOPENIA; PRIORITY JOURNAL; RASH; REVIEW; SIDE EFFECT; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE FUNCTION; THROMBOCYTOPENIA; THROMBOGENICITY; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ACUTE CORONARY SYNDROME; ANIMALS; ARTERIES; ATHEROSCLEROSIS; BLOOD PLATELETS; FIBRIN; FIBRINOLYTIC AGENTS; HEMOSTASIS; HUMANS; PLAQUE, ATHEROSCLEROTIC; THROMBIN; THROMBOSIS;

EID: 81255143017     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.2515     Document Type: Review

References (174)

1. Ross, R. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 340, 115-126 (1999).
2. Alwan, A. et al. Burden: mortality, morbidity and risk factors. in Global Status Report on Noncommunicable Diseases 2010 (ed. Alwan, A.) (WHO Press, Geneva, Switzerland, 2011).
3. Antithrombotic-Trialists-Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br. Med. J. 324, 71-86 (2002).
4. Bhatt, D.L. What makes platelets angry: diabetes, fibrinogen, obesity, and impaired response to antiplatelet therapy? J. Am. Coll. Cardiol. 52, 1060-1061 (2008).
5. Furie, B. & Furie, B.C. Mechanisms of thrombus formation. N. Engl. J. Med. 359, 938-949 (2008).
6. Ruggeri, Z.M. Platelets in atherothrombosis. Nat. Med. 8, 1227-1234 (2002). (Pubitemid 35373553)
7. Gawaz, M., Langer, H. & May, A.E. Platelets in inflammation and atherogenesis. J. Clin. Invest. 115, 3378-3384 (2005). (Pubitemid 43121822)
8. de Boer, O.J., van der Wal, A.C., Teeling, P. & Becker, A.E. Leucocyte recruitment in rupture prone regions of lipid-rich plaques: a prominent role for neovascularization? Cardiovasc. Res. 41, 443-449 (1999). (Pubitemid 29087340)
9. Kolodgie, F.D. et al. Intraplaque hemorrhage and progression of coronary atheroma. N. Engl. J. Med. 349, 2316-2325 (2003). (Pubitemid 37509739)
10. Burke, A.P. et al. Healed plaque ruptures and sudden coronary death: evidence that subclinical rupture has a role in plaque progression. Circulation 103, 934-940 (2001). (Pubitemid 32183797)
11. Libby, P. Inflammation in atherosclerosis. Nature 420, 868-874 (2002). (Pubitemid 36019640)
12. Davies, M.J., Fulton, W.F. & Robertson, W.B. The relation of coronary thrombosis to ischaemic myocardial necrosis. J. Pathol. 127, 99-110 (1979). (Pubitemid 9137059)
13. Falk, E. Plaque rupture with severe pre-existing stenosis precipitating coronary thrombosis. Characteristics of coronary atherosclerotic plaques underlying fatal occlusive thrombi. Br. Heart J. 50, 127-134 (1983). (Pubitemid 13027014)
14. Falk, E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation 71, 699-708 (1985). (Pubitemid 15099119)
15. Jackson, S.P. The growing complexity of platelet aggregation. Blood 109, 5087-5095 (2007). (Pubitemid 46890522)
16. Denis, C.V. & Wagner, D.D. Platelet adhesion receptors and their ligands in mouse models of thrombosis. Arterioscler. Thromb. Vasc. Biol. 27, 728-739 (2007). (Pubitemid 46606699)
17. Varga-Szabo, D., Pleines, I. & Nieswandt, B. Cell adhesion mechanisms in platelets. Arterioscler. Thromb. Vasc. Biol. 28, 403-412 (2008).
18. Ruggeri, Z.M. Platelet adhesion under flow. Microcirculation 16, 58-83 (2009).
19. Moroi, M. et al. Analysis of platelet adhesion to a collagen-coated surface under flow conditions: the involvement of glycoprotein VI in the platelet adhesion. Blood 88, 2081-2092 (1996). (Pubitemid 26307910)
20. Nieswandt, B. & Watson, S.P. Platelet-collagen interaction: is GPVI the central receptor? Blood 102, 449-461 (2003). (Pubitemid 36841960)
21. Santoro, S.A. Identification of a 160,000 dalton platelet membrane protein that mediates the initial divalent cation-dependent adhesion of platelets to collagen. Cell 46, 913-920 (1986). (Pubitemid 16027939)
22. Savage, B., Saldivar, E. & Ruggeri, Z.M. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell 84, 289-297 (1996). (Pubitemid 26040846)
23. Ruggeri, Z.M. Structure and function of von Willebrand factor. Thromb. Haemost. 82, 576-584 (1999).
24. Barg, A. et al. Soluble plasma-derived von Willebrand factor assembles to a haemostatically active filamentous network. Thromb. Haemost. 97, 514-526 (2007). (Pubitemid 46592927)
25. Siedlecki, C.A. et al. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor. Blood 88, 2939-2950 (1996). (Pubitemid 26357374)
26. Savage, B., Almus-Jacobs, F. & Ruggeri, Z.M. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell 94, 657-666 (1998). (Pubitemid 28427584)
27. Nesbitt, W.S. et al. A shear gradient-dependent platelet aggregation mechanism drives thrombus formation. Nat. Med. 15, 665-673 (2009).
28. Hantgan, R.R. Fibrin protofibril and fibrinogen binding to ADP-stimulated platelets: evidence for a common mechanism. Biochim. Biophys. Acta 968, 24-35 (1988). (Pubitemid 18030310)
29. Ruggeri, Z.M., Bader, R. & de Marco, L. Glanzmann thrombasthenia: deficient binding of von Willebrand factor to thrombin-stimulated platelets. Proc. Natl. Acad. Sci. USA 79, 6038-6041 (1982). (Pubitemid 13249974)
30. Bennett, J.S. & Vilaire, G. Exposure of platelet fibrinogen receptors by ADP and epinephrine. J. Clin. Invest. 64, 1393-1401 (1979).
31. Ni, H. et al. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J. Clin. Invest. 106, 385-392 (2000). (Pubitemid 30655638)
32. López, J.A., Andrews, R.K., Afshar-Kharghan, V. & Berndt, M.C. Bernard-Soulier syndrome. Blood 91, 4397-4418 (1998). (Pubitemid 28270285)
33. Shattil, S.J., Kim, C. & Ginsberg, M.H. The final steps of integrin activation: the end game. Nat. Rev. Mol. Cell Biol. 11, 288-300 (2010).
34. Hartwig, J.H., Barkalow, K., Azim, A. & Italiano, J. The elegant platelet: signals controlling actin assembly. Thromb. Haemost. 82, 392-398 (1999).
35. Reed, G.L. Platelet secretory mechanisms. Semin. Thromb. Hemost. 30, 441-450 (2004). (Pubitemid 39180719)
36. Jin, J., Daniel, J.L. & Kunapuli, S.P. Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J. Biol. Chem. 273, 2030-2034 (1998). (Pubitemid 28069249)
37. Hollopeter, G. et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 409, 202-207 (2001). (Pubitemid 32144286)
38. Huang, J.S., Ramamurthy, S.K., Lin, X. & Le Breton, G.C. Cell signalling through thromboxane A2 receptors. Cell. Signal. 16, 521-533 (2004). (Pubitemid 38125140)
39. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br. Med. J. 324, 71-86 (2002).
40. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348, 1329-1339 (1996).
41. Michelson, A.D. Antiplatelet therapies for the treatment of cardiovascular disease. Nat. Rev. Drug Discov. 9, 154-169 (2010).
42. Patrono, C., Baigent, C., Hirsh, J. & Roth, G. Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines 8th edn., Chest 133, 199S-233S (2008). (Pubitemid 351894914)
43. Coughlin, S.R. How the protease thrombin talks to cells. Proc. Natl. Acad. Sci. USA 96, 11023-11027 (1999). (Pubitemid 29487321)
44. Boucher, P. & Gotthardt, M. LRP and PDGF signaling: a pathway to atherosclerosis. Trends Cardiovasc. Med. 14, 55-60 (2004). (Pubitemid 38340847)
45. Davì, G. & Patrono, C. Platelet activation and atherothrombosis. N. Engl. J. Med. 357, 2482-2494 (2007).
46. Davies, M.J. A macro and micro view of coronary vascular insult in ischemic heart disease. Circulation 82, II38-II46 (1990).
47. Mann, J. & Davies, M.J. Mechanisms of progression in native coronary artery disease: role of healed plaque disruption. Heart 82, 265-268 (1999). (Pubitemid 29429594)
48. Kuijpers, M.J. et al. Complementary roles of platelets and coagulation in thrombus formation on plaques acutely ruptured by targeted ultrasound treatment: a novel intravital model. J. Thromb. Haemost. 7, 152-161 (2009).
49. Arbustini, E. et al. Coronary thrombosis in non-cardiac death. Coron. Artery Dis. 4, 751-759 (1993). (Pubitemid 23297396)
50. Bruschke, A.V. et al. The dynamics of progression of coronary atherosclerosis studied in 168 medically treated patients who underwent coronary arteriography three times. Am. Heart J. 117, 296-305 (1989). (Pubitemid 19059776)
51. Yokoya, K. et al. Process of progression of coronary artery lesions from mild or moderate stenosis to moderate or severe stenosis: a study based on four serial coronary arteriograms per year. Circulation 100, 903-909 (1999). (Pubitemid 29407169)
52. Hackett, D., Davies, G. & Maseri, A. Pre-existing coronary stenoses in patients with first myocardial infarction are not necessarily severe. Eur. Heart J. 9, 1317-1323 (1988). (Pubitemid 19043208)
53. Libby, P. Molecular bases of the acute coronary syndromes. Circulation 91, 2844-2850 (1995).
54. Badimon, J.J. et al. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. Circulation 99, 1780-1787 (1999). (Pubitemid 29181404)
55. Toschi, V. et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 95, 594-599 (1997). (Pubitemid 27063034)
56. Rekhter, M.D. Collagen synthesis in atherosclerosis: too much and not enough. Cardiovasc. Res. 41, 376-384 (1999). (Pubitemid 29087334)
57. Siess, W. Athero-and thrombogenic actions of lysophosphatidic acid and sphingosine-1-phosphate. Biochim. Biophys. Acta 1582, 204-215 (2002). (Pubitemid 34634131)
58. Siess, W. et al. Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions. Proc. Natl. Acad. Sci. USA 96, 6931-6936 (1999). (Pubitemid 29274987)
59. Mallat, Z. et al. Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity. Circulation 99, 348-353 (1999). (Pubitemid 29051259)
60. Arai, M. et al. Platelets with 10% of the normal amount of glycoprotein VI have an impaired response to collagen that results in a mild bleeding tendency. Br. J. Haematol. 89, 124-130 (1995).
61. Boylan, B. et al. Anti-GPVI-associated ITP: an acquired platelet disorder caused by autoantibody-mediated clearance of the GPVI/FcRγ-chain complex from the human platelet surface. Blood 104, 1350-1355 (2004). (Pubitemid 39166510)
62. Jandrot-Perrus, M. et al. Absent collagen-induced platelet activation in a patient double heterozygous for two GPVI mutations. in American Society for Hematology, Vol. 112, Abstract 88 (Blood, American Society for Hematology, 2008).
63. Moroi, M., Jung, S.M., Okuma, M. & Shinmyozu, K. A patient with platelets deficient in glycoprotein VI that lack both collagen-induced aggregation and adhesion. J. Clin. Invest. 84, 1440-1445 (1989). (Pubitemid 19272230)
64. Ryo, R. et al. Deficiency of P62, a putative collagen receptor, in platelets from a patient with defective collagen-induced platelet aggregation. Am. J. Hematol. 39, 25-31 (1992).
65. He, L. et al. The contributions of the α2 β1 integrin to vascular thrombosis in vivo. Blood 102, 3652-3657 (2003). (Pubitemid 37409384)
66. Massberg, S. et al. A crucial role of glycoprotein VI for platelet recruitment to the injured arterial wall in vivo. J. Exp. Med. 197, 41-49 (2003). (Pubitemid 36110256)
67. Grüner, S. et al. Anti-glycoprotein VI treatment severely compromises hemostasis in mice with reduced α2β1 levels or concomitant aspirin therapy. Circulation 110, 2946-2951 (2004). (Pubitemid 39473622)
68. Gkaliagkousi, E. & Ferro, A. Nitric oxide signalling in the regulation of cardiovascular and platelet function. Front. Biosci. 16, 1873-1897 (2011).
69. Cheng, Y. et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 296, 539-541 (2002). (Pubitemid 34408674)
70. Enjyoji, K. et al. Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. Nat. Med. 5, 1010-1017 (1999). (Pubitemid 29439571)
71. Marcus, A.J. et al. The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39. J. Clin. Invest. 99, 1351-1360 (1997). (Pubitemid 27142773)
72. Pinsky, D.J. et al. Elucidation of the thromboregulatory role of CD39/ectoapyrase in the ischemic brain. J. Clin. Invest. 109, 1031-1040 (2002). (Pubitemid 34408578)
73. Esmon, C.T. Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface. FASEB J. 9, 946-955 (1995).
74. Trip, M.D., Cats, V.M., van Capelle, F.J. & Vreeken, J. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N. Engl. J. Med. 322, 1549-1554 (1990). (Pubitemid 20176694)
75. Hirsh, J. Hyperactive platelets and complications of coronary artery disease. N. Engl. J. Med. 316, 1543-1544 (1987). (Pubitemid 17076241)
76. Rathbone, R.L., Ardlie, N.G. & Schwartz, C.J. Platelet aggregation and thrombus formation in diabetes mellitus: an in vitro study. Pathology 2, 307-316 (1970).
77. Lincoff, A.M. Important triad in cardiovascular medicine: diabetes, coronary intervention, and platelet glycoprotein IIb/IIIa receptor blockade. Circulation 107, 1556-1559 (2003). (Pubitemid 36378497)
78. Roffi, M. et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation 104, 2767-2771 (2001). (Pubitemid 33126648)
79. Hamet, P., Skuherska, R., Pang, S.C. & Tremblay, J. Abnormalities of platelet function in hypertension and diabetes. Hypertension 7, II135-II142 (1985).
80. Kjeldsen, S.E., Rostrup, M., Gjesdal, K. & Eide, I. The epinephrine-blood platelet connection with special reference to essential hypertension. Am. Heart J. 122, 330-336 (1991).
81. Opper, C. et al. Increased number of high sensitive platelets in hypercholesterolemia, cardiovascular diseases, and after incubation with cholesterol. Atherosclerosis 113, 211-217 (1995).
82. Terres, W., Becker, P. & Rosenberg, A. Changes in cardiovascular risk profile during the cessation of smoking. Am. J. Med. 97, 242-249 (1994). (Pubitemid 24284363)
83. Terres, W., Weber, K., Kupper, W. & Bleifeld, W. Age, cardiovascular risk factors and coronary heart disease as determinants of platelet function in men. A multivariate approach. Thromb. Res. 62, 649-661 (1991).
84. Ma, Y., Ashraf, M.Z. & Podrez, E.A. Scavenger receptor BI modulates platelet reactivity and thrombosis in dyslipidemia. Blood 116, 1932-1941 (2010).
85. Podrez, E.A. et al. Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat. Med. 13, 1086-1095 (2007). (Pubitemid 47517507)
86. Falk, E. Morphologic features of unstable atherothrombotic plaques underlying acute coronary syndromes. Am. J. Cardiol. 63, 114E-120E (1989). (Pubitemid 19074335)
87. Mailhac, A. et al. Effect of an eccentric severe stenosis on fibrin(ogen) deposition on severely damaged vessel wall in arterial thrombosis. Relative contribution of fibrin(ogen) and platelets. Circulation 90, 988-996 (1994).
88. Deplano, V. & Siouffi, M. Experimental and numerical study of pulsatile flows through stenosis: wall shear stress analysis. J. Biomech. 32, 1081-1090 (1999). (Pubitemid 29356047)
89. Long, Q., Xu, X.Y., Ramnarine, K.V. & Hoskins, P. Numerical investigation of physiologically realistic pulsatile flow through arterial stenosis. J. Biomech. 34, 1229-1242 (2001). (Pubitemid 32750634)
90. Wootton, D.M. & Ku, D.N. Fluid mechanics of vascular systems, diseases, and thrombosis. Annu. Rev. Biomed. Eng. 1, 299-329 (1999). (Pubitemid 129740014)
91. Lowe, G.D. Blood rheology in arterial disease. Clin. Sci. (Lond.) 71, 137-146 (1986). (Pubitemid 16059791)
92. O'Brien, J.R. Shear-induced platelet aggregation. Lancet 335, 711-713 (1990). (Pubitemid 20089317)
93. Brown, B.G. et al. Incomplete lysis of thrombus in the moderate underlying atherosclerotic lesion during intracoronary infusion of streptokinase for acute myocardial infarction: quantitative angiographic observations. Circulation 73, 653-661 (1986). (Pubitemid 16081423)
94. Mizuno, K. et al. Angioscopic coronary macromorphology in patients with acute coronary disorders. Lancet 337, 809-812 (1991).
95. Mizuno, K. et al. Angioscopic evaluation of coronary-artery thrombi in acute coronary syndromes. N. Engl. J. Med. 326, 287-291 (1992).
96. Owens, A.P. III & Mackman, N. Microparticles in hemostasis and thrombosis. Circ. Res. 108, 1284-1297 (2011).
97. Gross, P.L., Furie, B.C., Merrill-Skoloff, G., Chou, J. & Furie, B. Leukocyte-versus microparticle-mediated tissue factor transfer during arteriolar thrombus development. J. Leukoc. Biol. 78, 1318-1326 (2005). (Pubitemid 41779238)
98. Kleinschnitz, C. et al. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J. Exp. Med. 203, 513-518 (2006).
99. Renné, T. et al. Defective thrombus formation in mice lacking coagulation factor XII. J. Exp. Med. 202, 271-281 (2005). (Pubitemid 41043823)
100. Rosen, E.D., Gailani, D. & Castellino, F.J. FXI is essential for thrombus formation following FeCl3-induced injury of the carotid artery in the mouse. Thromb. Haemost. 87, 774-776 (2002). (Pubitemid 34302972)
101. Salomon, O., Steinberg, D.M., Koren-Morag, N., Tanne, D. & Seligsohn, U. Reduced incidence of ischemic stroke in patients with severe factor XI deficiency. Blood 111, 4113-4117 (2008).
102. Zhang, H. et al. Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. Blood 116, 4684-4692 (2010).
103. Caen, J. & Wu, Q. Hageman factor, platelets and polyphosphates: early history and recent connection. J. Thromb. Haemost. 8, 1670-1674 (2010).
104. Müller, F. et al. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell 139, 1143-1156 (2009).
105. Hagedorn, I. et al. Factor XIIa inhibitor recombinant human albumin Infestin-4 abolishes occlusive arterial thrombus formation without affecting bleeding. Circulation 121, 1510-1517 (2010).
106. Bevers, E.M. & Williamson, P.L. Phospholipid scramblase: an update. FEBS Lett. 584, 2724-2730 (2010).
107. Weiss, H.J., Vicic, W.J., Lages, B.A. & Rogers, J. Isolated deficiency of platelet procoagulant activity. Am. J. Med. 67, 206-213 (1979). (Pubitemid 9239513)
108. Suzuki, J., Umeda, M., Sims, P.J. & Nagata, S. Calcium-dependent phospholipid scrambling by TMEM16F. Nature 468, 834-838 (2010).
109. Bergmeier, W. et al. R93W mutation in Orai1 causes impaired calcium influx in platelets. Blood 113, 675-678 (2009).
110. Braun, A. et al. Orai1 (CRACM1) is the platelet SOC channel and essential for pathological thrombus formation. Blood 113, 2056-2063 (2009).
111. Jackson, S.P. & Schoenwaelder, S.M. Procoagulant platelets: are they necrotic? Blood 116, 2011-2018 (2010).
112. Schoenwaelder, S.M. et al. Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function. Blood 114, 663-666 (2009).
113. Denis, C. et al. A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis. Proc. Natl. Acad. Sci. USA 95, 9524-9529 (1998). (Pubitemid 28506264)
114. Falati, S., Gross, P., Merrill-Skoloff, G., Furie, B.C. & Furie, B. Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse. Nat. Med. 8, 1175-1181 (2002).
115. Kulkarni, S. et al. A revised model of platelet aggregation. J. Clin. Invest. 105, 783-791 (2000). (Pubitemid 30164117)
116. Nieswandt, B., Aktas, B., Moers, A. & Sachs, U.J. Platelets in atherothrombosis: lessons from mouse models. J. Thromb. Haemost. 3, 1725-1736 (2005). (Pubitemid 41716559)
117. Holtkötter, O. et al. Integrin α2-deficient mice develop normally, are fertile, but display partially defective platelet interaction with collagen. J. Biol. Chem. 277, 10789-10794 (2002). (Pubitemid 34952832)
118. Kato, K. et al. The contribution of glycoprotein VI to stable platelet adhesion and thrombus formation illustrated by targeted gene deletion. Blood 102, 1701-1707 (2003). (Pubitemid 37022563)
119. Kato, K. et al. Genetic deletion of mouse platelet glycoprotein Ibβ produces a Bernard-Soulier phenotype with increased α-granule size. Blood 104, 2339-2344 (2004). (Pubitemid 39331831)
120. Mangin, P. et al. Thrombin overcomes the thrombosis defect associated with platelet GPVI/FcRγdeficiency. Blood 107, 4346-4353 (2006). (Pubitemid 43801360)
121. Nieswandt, B. et al. Glycoprotein VI but not α2β1 integrin is essential for platelet interaction with collagen. EMBO J. 20, 2120-2130 (2001). (Pubitemid 32410582)
122. Poole, A. et al. The Fc receptor γ-chain and the tyrosine kinase Syk are essential for activation of mouse platelets by collagen. EMBO J. 16, 2333-2341 (1997). (Pubitemid 27258634)
123. Ware, J., Russell, S. & Ruggeri, Z.M. Generation and rescue of a murine model of platelet dysfunction: the Bernard-Soulier syndrome. Proc. Natl. Acad. Sci. USA 97, 2803-2808 (2000). (Pubitemid 30159252)
124. Hodivala-Dilke, K.M. et al. β3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J. Clin. Invest. 103, 229-238 (1999). (Pubitemid 29053141)
125. Smyth, S.S., Reis, E.D., Vaananen, H., Zhang, W. & Coller, B.S. Variable protection of β3-integrin-deficient mice from thrombosis initiated by different mechanisms. Blood 98, 1055-1062 (2001).
126. Tronik-Le Roux, D. et al. Thrombasthenic mice generated by replacement of the integrin αIIb gene: demonstration that transcriptional activation of this megakaryocytic locus precedes lineage commitment. Blood 96, 1399-1408 (2000). (Pubitemid 30658470)
127. Wei, A.H., Schoenwaelder, S.M., Andrews, R.K. & Jackson, S.P. New insights into the haemostatic function of platelets. Br. J. Haematol. 147, 415-430 (2009).
128. Sugidachi, A. et al. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite. J. Thromb. Haemost. 5, 1545-1551 (2007). (Pubitemid 46965386)
129. Jernberg, T. et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur. Heart J. 27, 1166-1173 (2006).
130. van Giezen, J.J. & Humphries, R.G. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin. Thromb. Hemost. 31, 195-204 (2005). (Pubitemid 40605194)
131. Anderson, J.L. et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 116, e148-e304 (2007).
132. Kushner, F.G. et al. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 120, 2271-2306 (2009).
133. Fisher, M. & Loscalzo, J. The perils of combination antithrombotic therapy and potential resolutions. Circulation 123, 232-235 (2011).
134. Sørensen, R. et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet 374, 1967-1974 (2009).
135. Sobieraj-Teague, M., Gallus, A.S. & Eikelboom, J.W. The risk of iatrogenic bleeding in acute coronary syndromes and long-term mortality. Curr. Opin. Cardiol. 23, 327-334 (2008). (Pubitemid 351787097)
136. Rao, S.V. et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. J. Am. Med. Assoc. 292, 1555-1562 (2004). (Pubitemid 39314961)
137. Doyle, B.J., Rihal, C.S., Gastineau, D.A. & Holmes, D.R. Jr. Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: implications for contemporary practice. J. Am. Coll. Cardiol. 53, 2019-2027 (2009).
138. Coughlin, S.R. Thrombin signalling and protease-activated receptors. Nature 407, 258-264 (2000).
139. Becker, R.C. et al. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet 373, 919-928 (2009).
140. Hurlen, M., Abdelnoor, M., Smith, P., Erikssen, J. & Arnesen, H. Warfarin, aspirin, or both after myocardial infarction. N. Engl. J. Med. 347, 969-974 (2002).
141. Yousuf, O. & Bhatt, D.L. The evolution of antiplatelet therapy in cardiovascular disease. Nat. Rev. Cardiol. 8, 547-559 (2011).
142. Dubois, C., Panicot-Dubois, L., Merrill-Skoloff, G., Furie, B. & Furie, B.C. Glycoprotein VI-dependent and-independent pathways of thrombus formation in vivo. Blood 107, 3902-3906 (2006). (Pubitemid 43726794)
143. Konstantinides, S. et al. Distinct antithrombotic consequences of platelet glycoprotein Ibα and VI deficiency in a mouse model of arterial thrombosis. J. Thromb. Haemost. 4, 2014-2021 (2006). (Pubitemid 44226783)
144. Falati, S. et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J. Exp. Med. 197, 1585-1598 (2003). (Pubitemid 36682554)
145. Miszti-Blasius, K., Debreceni, I.B., Felszeghy, S., Dezso, B. & Kappelmayer, J. Lack of P-selectin glycoprotein ligand-1 protects mice from thrombosis after collagen/epinephrine challenge. Thromb. Res. 127, 228-234 (2011).
146. Hechler, B. et al. A role of the fast ATP-gated P2X1 cation channel in thrombosis of small arteries in vivo. J. Exp. Med. 198, 661-667 (2003). (Pubitemid 37040400)
147. Ghosh, A. et al. Platelet CD36 mediates interactions with endothelial cell-derived microparticles and contributes to thrombosis in mice. J. Clin. Invest. 118, 1934-1943 (2008). (Pubitemid 351632395)
148. Nanda, N. et al. Platelet aggregation induces platelet aggregate stability via SLAM family receptor signaling. Blood 106, 3028-3034 (2005). (Pubitemid 41565895)
149. Zhu, L. et al. Regulated surface expression and shedding support a dual role for semaphorin 4D in platelet responses to vascular injury. Proc. Natl. Acad. Sci. USA 104, 1621-1626 (2007). (Pubitemid 46214640)
150. Ni, H. et al. Plasma fibronectin promotes thrombus growth and stability in injured arterioles. Proc. Natl. Acad. Sci. USA 100, 2415-2419 (2003). (Pubitemid 36297513)
151. Matuskova, J. et al. Decreased plasma fibronectin leads to delayed thrombus growth in injured arterioles. Arterioscler. Thromb. Vasc. Biol. 26, 1391-1396 (2006). (Pubitemid 44305387)
152. André, P. et al. CD40L stabilizes arterial thrombi by a β3 integrin-dependent mechanism. Nat. Med. 8, 247-252 (2002). (Pubitemid 34250102)
153. Angelillo-Scherrer, A. et al. Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. Nat. Med. 7, 215-221 (2001). (Pubitemid 32148489)
154. Li, D., D'Angelo, L., Chavez, M. & Woulfe, D.S. Arrestin-2 differentially regulates PAR4 and ADP receptor signaling in platelets. J. Biol. Chem. 286, 3805-3814 (2011).
155. Elvers, M. et al. Impaired αIIbβ3 integrin activation and shear-dependent thrombus formation in mice lacking phospholipase D1. Sci. Signal. 3, ra1 (2010).
156. Martin, V. et al. Deletion of the p110β isoform of phosphoinositide 3-kinase in platelets reveals its central role in Akt activation and thrombus formation in vitro and in vivo. Blood 115, 2008-2013 (2010).
157. Nagy, B. Jr. et al. Impaired activation of platelets lacking protein kinase C-θ isoform. Blood 113, 2557-2567 (2009).
158. Wang, X. et al. Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice. J. Thromb. Haemost. 3, 695-702 (2005). (Pubitemid 41647883)
159. Goto, S., Ogawa, H., Takeuchi, M., Flather, M.D. & Bhatt, D.L. Double-blind, placebo-controlled phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease. Eur. Heart J. 31, 2601-2613 (2010).
160. Lesault, P.-F. et al. Daily administration of the TP receptor antagonist terutroban improved endothelial function in high-cardiovascular-risk patients with atherosclerosis. Br. J. Clin. Pharmacol. 71, 844-851 (2011).
161. Muller, J.E. Coronary artery thrombosis: historical aspects. J. Am. Coll. Cardiol. 1, 893-896 (1983). (Pubitemid 13058409)
162. Weisse, A.B. The elusive clot: the controversy over coronary thrombosis in myocardial infarction. J. Hist. Med. Allied Sci. 61, 66-78 (2006). (Pubitemid 41795264)
163. Hammer, A. Ein Fall von thrombotischem Verschlusse einer der Kranzarterien des Herzens. Wien. Med. Wochenschr. 28, 97-102 (1878).
164. Payne, J.F. Two cases of sudden death from affection of the heart, examined in post mortem theatre. BMJ 1, 130-131 (1870).
165. Vulpian, E.F.A. Ramollissement cerebral. Caillot ancien dans l'auricle
166. Herrick, J.B. Clinical features of sudden obstruction of the coronary arteries. J. Am. Med. Assoc. 59, 2015-2020 (1912).
167. Ehrlich, J.C. & Shinohara, Y. Low incidence of coronary thrombosis in myocardial infarction. A restudy by serial block technique. Arch. Pathol. 78, 432-445 (1964).
168. Friedberg, C.K. & Horn, H. Myocardial infarction with and without acute coronary occlusion. J. Am. Med. Assoc. 112, 1675-1679 (1939).
169. Miller, R.D., Burchell, H.B. & Edwards, J.E. Myocardial infarction with and without acute coronary occlusion; a pathologic study. AMA Arch. Intern. Med. 88, 597-604 (1951).
170. DeWood, M.A. et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N. Engl. J. Med. 303, 897-902 (1980). (Pubitemid 10021186)
171. Chazov, E.I. et al. Intracoronary administration of fibrinolysin in acute myocardial infarct. Ter. Arkh. 48, 8-19 (1976).
172. Rentrop, K.P. et al. Acute myocardial infarction: intracoronary application of nitroglycerin and streptokinase. Clin. Cardiol. 2, 354-363 (1979). (Pubitemid 10181856)
173. Bizzozero, G. Su di un nuovo elemento morfologico del sangue de mammiferi e della sua importanza nella trombosi e nella coagulazione. L'Osservatore 17, 785-787 (1881).
174. Bizzozero, G. Ueber einen neunen Forrnbestandteil des Blutes und dessen Rolle bei der Thrombose und Blut perinnung. Virchows Arch. Pathol. Anat. Physiol. Klin. Med. 90, 261-332 (1882).